Amneal Pharmaceuticals (AMRX) Net Cash Flow (2017 - 2026)

Amneal Pharmaceuticals has reported Net Cash Flow for 10 years, with the latest figure at -$64.6 million in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 514.66% year-over-year to -$64.6 million in Q2 2026; TTM through Jun 2026 was $58.0 million, a 63.21% increase from a year earlier, with the FY2025 full-year figure at $196.2 million, up 865.93% from the prior year.
• Net Cash Flow was -$64.6 million for Q2 2026 at Amneal Pharmaceuticals, up from -$107.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $155.4 million in Q3 2025, with the low at -$118.4 million in Q2 2022.
• Average Net Cash Flow over 5 years is -$6.0 million, with a median of -$10.3 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow sank 885.96% in 2023, then jumped 1137.19% in 2024.
• Over 5 years, Net Cash Flow stood at -$56.9 million in 2022, then surged by 105.8% to $3.3 million in 2023, then surged by 1137.19% to $40.8 million in 2024, then soared by 83.12% to $74.7 million in 2025, then plunged by 186.47% to -$64.6 million in 2026.
• The last three Net Cash Flow figures came in at -$64.6 million (Q2 2026), -$107.5 million (Q1 2026), and $74.7 million (Q4 2025), per Business Quant data.